ENTERA HEALTH, INC. ANNOUNCES PRESENTATIONS AT DIGESTIVE DISEASE WEEK (DDW) 2015 IN WASHINGTON, D.C.

Entera Health, Inc. today announces three poster presentations that will take place at the Digestive Disease Week 2015 Annual Meeting in Washington, D.C., from Saturday, May 16th – Tuesday, May 19th, 2015.

DDW 2015 Poster ID: SU1177

Sunday, May 17th, 2015 -- 12:00 pm – 2:00 PM

Efficacy of Serum-derived Bovine Immunoglobulin/Protein Isolate (SBI) in Pediatric Patient with Acute Diarrhea Due to Small Intestinal Bacteria Overgrowth. Thomas L. Taxman, MD, The Institute For Women's & Children's Health, Beachwood, OH

DDW 2015 Poster ID: Mo1708

Monday, May 18th, 2015 (12:00 -2:00 PM)

Improved Tryptophan Metabolism and Decreased Inflammation Following Administration of Serum-Derived Bovine Immunoglobulin Isolate in a Mouse Model of IBD. Christopher J Detzel, PhD, Entera Health, Ankeny, IA

DDW 2015 Poster ID: Tu2011

Tuesday, May 19th, 2015 (12:00 -2:00 PM)

Resolution of Antibiotic-Induced and Idiopathic Diarrhea in Infants with a Serum-Derived Bovine Immunoglobulin Preparation.

Manisha Dave, MD, Texas Digestive Disease Consultants, Plano, TX

About EnteraGam®

EnteraGam® is a prescription medical food product intended to provide for distinctive nutritional requirements that are unique for the clinical dietary management of specific intestinal disorders [e.g., in irritable bowel syndrome with diarrhea (IBS-D), inflammatory bowel disease (IBD), and HIV associated enteropathy]. EnteraGam® is required to be used under physician supervision as part of ongoing medical care for a specific condition or disease. EnteraGam® is also indicated for the clinical dietary management of enteropathy in patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients. For full prescribing information, please visit our product website at http://enteragam.com/.

Important Safety Information

EnteraGam® is a specially formulated protein source for the management of intestinal disorders. The product has been extremely well tolerated for up to a year in HIV patients and up to 8 months in infants. The major side effects in clinical trials (2-5%) have included mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam® is contraindicated for patients with a hypersensitivity (allergy) to beef, or any components in EnteraGam®. Therefore, patients who have an allergy to beef or any component of EnteraGam® should not take this product. EnteraGam® has not been studied in pregnant and nursing mothers. The choice to administer EnteraGam® in pregnant or nursing mothers is at the clinical discretion of the physician. Medical foods like EnteraGam® are required by FDA regulations to be dosed and monitored by physicians as part of ongoing care for patients with chronic conditions or diseases.

About Entera Health, Inc.

Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. Our passion is to help people thrive through healthier living. Our motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Visit us at http://www.enterahealth.com/.

For questions, please contact:
Tom Heck, Chief Operating Officer
515-963-7560
Tom.Heck@enterahealth.com

View Press Release Online

Contact Us

LEAVE YOUR CONTACT INFORMATION BELOW




Message: